Cid16020046

SBFI-103 (9-Fluorenylmethyl a-3-hydroxycarbonyl-2,4-di(2-methoxylphenyl)-cyclobutane-1-carboxylate), a selective inhibitor of FABP-5 with negligible affinity for FABP-3 and FABP-7, was synthesized as previously described (Yan et al. 2018 ). SBFI-103 was administered in 2 doses (0.5 or 5 μg/side). Other drugs (Cayman Chemical): CB1R inverse agonist SR141716 (rimonabant; 0.5 μg/side), CB2R inverse agonist AM630 (5 μg/side), GPR55 antagonist CID16020046 (1 μg/side), and PPARγ antagonist T0070907 (0.2 μg/side) were co-administered with 5 μg SBFI-103 or vehicle. The doses of the drugs were determined by our pilot studies and previous studies in the literature, and are inversely proportional to the K i values of their respective target receptors (Zhang et al. 2014; Loureiro et al. 2016; Kramar et al. 2017 ). All drugs were dissolved in saline containing 10% DMSO-5% Cremophor and infused bilaterally (volume: 0.5 μL/side, rate of infusion: 0.5 μL/min) using a 10 μL Hamilton syringe with Polymicro capillary tubing protruding 1 mm beyond the implanted guide cannula. Each behavioral test commenced 5 min after the micro-infusions.